Lamivudine treatment enabling right hepatectomy for hepatocellular carcinoma in decompensated cirrhosis

First Department of Internal Medicine, Oita University, Oita 879-5593, Japan.
World Journal of Gastroenterology (Impact Factor: 2.37). 05/2012; 18(20):2586-90. DOI: 10.3748/wjg.v18.i20.2586
Source: PubMed


A 69-year-old man was admitted to our hospital in October 2003, for further examination of two liver tumors. He was diagnosed with hepatocellular carcinoma (HCC) arising from decompensated hepatitis B virus (HBV)-related cirrhosis. Long-term lamivudine administration improved liver function dramatically despite repeated treatment for HCC. His Child-Pugh score was 9 points at start of lamivudine treatment, improving to 5 points after 1 year. His indocyanine green at 15 min after injection test score was 48% before lamivudine treatment, improving to 22% after 2 years and to 5% after 4 years. Radiofrequency ablation controlled the HCC foci and maintained his liver function. In April 2009, abdominal computed tomography revealed a tumor thrombus in the right portal vein. Since his indocyanine green test results had improved to less than 10%, we performed a right hepatectomy, which was successful. To our knowledge, there have been no documented reports of patients undergoing successful right hepatectomy for HCC arising from decompensated cirrhosis. The findings observed in our patient indicate the importance of nucleoside analogs for treating HBV-related HCC.

Download full-text


Available from: Masataka Seike
  • [Show abstract] [Hide abstract]
    ABSTRACT: Lamivudine is used for the treatment of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). However, HBV-related HCC patients with mutations in the tyrosine-methionine-aspartate-aspartate (YMDD) motif have no response to lamivudine therapy. The detection of YMDD mutations in HBV-related HCC patients may help guide the treatment of HCC. In this study, a simple, sensitive, reliable and cost-effective hybridization-fluorescence polarization assay for the detection of YMDD mutations in HCC was developed. A pair of general primers within the highly conserved region of the HBV polymerase gene was used in an asymmetric PCR. Three probes specific for the corresponding YMDD mutations labeled with different fluorescent reporters hybridized to their target amplicons, and hybridization was indicated by higher fluorescence polarization. The hybridization-fluorescence polarization assay was capable of detecting YMDD mutations at a limit of detection of 10 copies per reaction, and the assay was able to detect minor populations of viruses with primary YMDD mutations as low as 10%. The rates of primary YMDD mutations and the correlation between YMDD mutations and HBV genotypes in 251 HBV-related HCC patients were investigated using the hybridization-fluorescence polarization assay.
    No preview · Article · Nov 2012 · Journal of virological methods
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Methods: A total of 266 patients with chronic CHB were included. They all underwent optimized treatment, including 97 patients treated with telbivudine tablets, 92 with entecavir tablets, and 77 with adefovir dipivoxil tablets. The undectable rates of HBV DNA at 12, 24 and 108 wk, the recovery rate of alanine aminotransferase (ALT), the disappearance rate of hepatitis B e antigen (HBeAg), and the conversion rate of HBeAg were compared. The Child-Pugh stage prior treatment and at 108 wk posttreatment as well as adverse reactions were also compared.
    Preview · Article · Jan 2015
  • Source
    Research: effectivness
    [Show description] [Hide description]
    DESCRIPTION: effectiveness of HBV vaccination during infancy
    Full-text · Research · Nov 2015